Northwest Biotherapeutics, Inc.
$0.26
Stock Quotes & Analysis
NWBO0.46%
$0.26
Latest AAPL News (Need to figure out how to make this dynamic)
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The ballots have been counted, the speeches have been made, and the confetti has settled.…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Northwest Biotherapeutics, Inc.Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: NWBO
Exchange: OQB
Employees: 25
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
 | 4800 Montgomery Lane, Bethesda, MD, United States |
 | 240 497 9024 |
 | https://www.nwbio.com |